Trials / Active Not Recruiting
Active Not RecruitingNCT01252953
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30,449 (actual)
- Sponsor
- University of Oxford · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events) in patients with circulatory problems who have their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.
Detailed description
Sub-study: Does anacetrapib as a CETP inhibitor lead to mobilization of stem cells and enhance myocardial function via neoangiogenesis and tissue regeneration? Following the main on-treatment part of the study, there was a further period of at least 2 years during which participants were followed-up by telephone, off treatment. All participants stopped study treatment prior to February 2017 (results for the main-trial have been reported) and direct participant follow-up was completed in April 2019. In the UK we will continue to collect information on health outcomes via central data registries and NHS sources for many years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anacetrapib | tablet, 100mg daily |
| DRUG | Placebo anacetrapib | tablet, 1 tablet daily |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2017-01-31
- Completion
- 2037-01-31
- First posted
- 2010-12-03
- Last updated
- 2024-06-25
- Results posted
- 2018-05-04
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01252953. Inclusion in this directory is not an endorsement.